Truvestments Capital LLC Invests $39,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 37 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Sachetta LLC raised its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares in the last quarter. Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Finally, Family Firm Inc. acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on REGN. Oppenheimer dropped their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Finally, Truist Financial cut their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ REGN opened at $754.87 on Thursday. The company has a 50 day simple moving average of $921.45 and a 200 day simple moving average of $1,022.55. The firm has a market cap of $82.95 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.